{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:51:30Z","timestamp":1790704290750,"version":"4.1.0"},"reference-count":149,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T00:00:00Z","timestamp":1677369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz","award":["503\/1-151-07\/503-11-001-18"],"award-info":[{"award-number":["503\/1-151-07\/503-11-001-18"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a serious health problem due to its high incidence and consequences. In view of the existing controversies, new therapeutic options for NAFLD are still being sought. Therefore, the aim of our review was to evaluate the recently published studies on the treatment of NAFLD patients. We searched for articles in the PubMed database using appropriate terms, including \u201cnon-alcoholic fatty liver disease\u201d, \u201cnonalcoholic fatty liver disease\u201d, \u201cNAFLD\u201d, \u201cdiet\u201d, \u201ctreatment\u201d, \u201cphysical activity\u201d, \u201csupplementation\u201d, \u201csurgery\u201d, \u201coverture\u201d and \u201cguidelines\u201d. One hundred forty-eight randomized clinical trials published from January 2020 to November 2022 were used for the final analysis. The results show significant benefits of NAFLD therapy associated with the use of not only the Mediterranean but also other types of diet (including low-calorie ketogenic, high-protein, anti-inflammatory and whole-grain diets), as well as enrichment with selected food products or supplements. Significant benefits in this group of patients are also associated with moderate aerobic physical training. The available therapeutic options indicate, above all, the usefulness of drugs related to weight reduction, as well as the reduction in insulin resistance or lipids level and drugs with anti-inflammatory or antioxidant properties. The usefulness of therapy with dulaglutide and the combination of tofogliflozin with pioglitazone should be emphasized. Based on the results of the latest research, the authors of this article suggest a revision of the therapeutic recommendations for NAFLD patients.<\/jats:p>","DOI":"10.3390\/jcm12051852","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T02:04:11Z","timestamp":1677463451000},"page":"1852","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["What\u2019s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0609-9657","authenticated-orcid":false,"given":"Marcin","family":"Kosmalski","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Frankowski","sequence":"additional","affiliation":[{"name":"Students\u2019 Research Club, Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-3853","authenticated-orcid":false,"given":"Sylwia","family":"Zi\u00f3\u0142kowska","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"R\u00f3\u017cycka-Kosmalska","sequence":"additional","affiliation":[{"name":"Department of Clinical Electrocardiology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Pietras","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102866","DOI":"10.1016\/j.ctim.2022.102866","article-title":"Comparison of Delta-Tocotrienol and Alpha-Tocopherol Effects on Hepatic Steatosis and Inflammatory Biomarkers in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blind Active-Controlled Trial","volume":"70","author":"Pervez","year":"2022","journal-title":"Complement. Ther. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kosmalski, M., Zi\u00f3\u0142kowska, S., Czarny, P., Szemraj, J., and Pietras, T. (2022). The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051375"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pantic, I., Lugonja, S., Rajovic, N., Dumic, I., and Milovanovic, T. (2021). Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?. Medicina, 58.","DOI":"10.3390\/medicina58010038"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Osorio-Conles, \u00d3., Vega-Beyhart, A., Ibarzabal, A., Balibrea, J.M., Graupera, I., Rimola, J., Vidal, J., and de Hollanda, A. (2021). A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910541"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., and Assi, H.I. (2022). Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020786"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD Identifies Patients with Significant Hepatic Fibrosis Better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tang, A., Ng, C.H., Phang, P.H., Chan, K.E., Chin, Y.H., Fu, C.E., Zeng, R.W., Xiao, J., Tan, D.J.H., and Quek, J. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-Lean NAFLD\u2014A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 2022. in press.","DOI":"10.1016\/j.cgh.2022.06.029"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Calabrese, F.M., Disciglio, V., Franco, I., Sorino, P., Bonfiglio, C., Bianco, A., Campanella, A., Lippolis, T., Pesole, P.L., and Polignano, M. (2022). A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients. Nutrients, 14.","DOI":"10.3390\/nu14091773"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) Score for the Non-Invasive Identification of Patients with Non-Alcoholic Steatohepatitis with Significant Activity and Fibrosis: A Prospective Derivation and Global Validation Study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.dsx.2020.07.049","article-title":"Nonalcoholic Fatty Liver Disease in Males with Low Testosterone Concentrations","volume":"14","author":"Polyzos","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pacheco, L.S., Bradley, R.D., Anderson, C.A.M., and Allison, M.A. (2022). Changes in Biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) upon Access to Avocados in Hispanic\/Latino Adults: Secondary Data Analysis of a Cluster Randomized Controlled Trial. Nutrients, 14.","DOI":"10.3390\/nu14132744"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8833287","DOI":"10.1155\/2021\/8833287","article-title":"Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children","volume":"2021","author":"Ye","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-Alcoholic Fatty Liver Disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr. Diabetes Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a Driver of Chronic Kidney Disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1111\/jcmm.17456","article-title":"A Randomized, Placebo-controlled Clinical Trial of Hydrogen\/Oxygen Inhalation for Non-alcoholic Fatty Liver Disease","volume":"26","author":"Tao","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41467-022-29968-0","article-title":"A Randomized Controlled Trial for Response of Microbiome Network to Exercise and Diet Intervention in Patients with Nonalcoholic Fatty Liver Disease","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-Alcoholic Fatty Liver Disease: A Patient Guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ristic-Medic, D., Kovacic, M., Takic, M., Arsic, A., Petrovic, S., Paunovic, M., Jovicic, M., and Vucic, V. (2020). Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. Nutrients, 13.","DOI":"10.3390\/nu13010015"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fendo.2020.00607","article-title":"Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity","volume":"11","author":"Cunha","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Crabtree, C., Kackley, M., Buga, A., Fell, B., LaFountain, R., Hyde, P., Sapper, T., Kraemer, W., Scandling, D., and Simonetti, O. (2021). Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults. Nutrients, 13.","DOI":"10.3390\/nu13030966"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e14802","DOI":"10.2196\/14802","article-title":"Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial","volume":"8","author":"Lim","year":"2020","journal-title":"JMIR mHealth uHealth"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/liv.14916","article-title":"Effects of Lifestyle Interventions on Epigenetic Signatures of Liver Fat: Central Randomized Controlled Trial","volume":"41","author":"Keller","year":"2021","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Montemayor, S., Mascar\u00f3, C.M., Ugarriza, L., Casares, M., Llompart, I., Abete, I., Zulet, M.\u00c1., Mart\u00ednez, J.A., Tur, J.A., and Bouzas, C. (2022). Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study. Nutrients, 14.","DOI":"10.3390\/nu14153186"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Campanella, A., Iacovazzi, P.A., Misciagna, G., Bonfiglio, C., Mirizzi, A., Franco, I., Bianco, A., Sorino, P., Caruso, M.G., and Cisternino, A.M. (2020). The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis. Nutrients, 12.","DOI":"10.3390\/nu12061674"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The Effectiveness and Acceptability of Mediterranean Diet and Calorie Restriction in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/liv.15264","article-title":"Impact of a Mediterranean Diet on Hepatic and Metabolic Outcomes in non-alcoholic Fatty Liver Disease: The MEDINA Randomised Controlled Trial","volume":"42","author":"George","year":"2022","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00231","DOI":"10.14309\/ctg.0000000000000231","article-title":"Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease","volume":"11","author":"Scragg","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Franco, I., Bianco, A., Mirizzi, A., Campanella, A., Bonfiglio, C., Sorino, P., Notarnicola, M., Tutino, V., Cozzolongo, R., and Giannuzzi, V. (2020). Physical Activity and Low Glycemic Index Mediterranean Diet: Main and Modification Effects on NAFLD Score. Results from a Randomized Clinical Trial. Nutrients, 13.","DOI":"10.3390\/nu13010066"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/liv.14596","article-title":"High-protein Diet More Effectively Reduces Hepatic Fat than Low-protein Diet despite Lower Autophagy and FGF21 Levels","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nutres.2019.08.009","article-title":"An Energy-Restricted High-Protein Diet Supplemented with \u03b2-Cryptoxanthin Alleviated Oxidative Stress and Inflammation in Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"73","author":"Haidari","year":"2020","journal-title":"Nutr. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1017\/S0007114519002769","article-title":"Whole-Grain Consumption and Its Effects on Hepatic Steatosis and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: A Randomised Controlled Clinical Trial","volume":"123","author":"Dorosti","year":"2020","journal-title":"Br. J. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2000991","DOI":"10.1002\/mnfr.202000991","article-title":"Effects of Insoluble Cereal Fibre on Body Fat Distribution in the Optimal Fibre Trial","volume":"65","author":"Kabisch","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/liv.14818","article-title":"Effects of Two Personalized Dietary Strategies during a 2-year Intervention in Subjects with Nonalcoholic Fatty Liver Disease: A Randomized Trial","volume":"41","author":"Cantero","year":"2021","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mohamad Nor, M.H., Ayob, N., Mokhtar, N.M., Raja Ali, R.A., Tan, G.C., Wong, Z., Shafiee, N.H., Wong, Y.P., Mustangin, M., and Nawawi, K.N.M. (2021). The Effect of Probiotics (MCP\u00ae BCMC\u00ae Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 13.","DOI":"10.3390\/nu13093192"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clnesp.2021.06.015","article-title":"Effect of Omega-3 Supplementation on Fatty Liver and Visceral Adiposity Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"44","author":"Sangouni","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/bmjdrc-2019-000871","article-title":"Hepatic de Novo Lipogenesis Is Suppressed and Fat Oxidation Is Increased by Omega-3 Fatty Acids at the Expense of Glucose Metabolism","volume":"8","author":"Green","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cansan\u00e7\u00e3o, K., Citelli, M., Carvalho Leite, N., L\u00f3pez de las Hazas, M.-C., D\u00e1valos, A., Tavares do Carmo, M.d.G., and Peres, W.A.F. (2020). Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. Nutrients, 12.","DOI":"10.3390\/nu12113372"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111659","DOI":"10.1016\/j.nut.2022.111659","article-title":"Concentrated Fish Oil Ameliorates Non-Alcoholic Fatty Liver Disease by Regulating Fibroblast Growth Factor 21-Adiponectin Axis","volume":"99\u2013100","author":"Guo","year":"2022","journal-title":"Nutrition"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1017\/S0007114520000495","article-title":"Combined Effect of n -3 Fatty Acids and Phytosterol Esters on Alleviating Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease Subjects: A Double-Blind Placebo-Controlled Clinical Trial","volume":"123","author":"Song","year":"2020","journal-title":"Br. J. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of Probiotic and Prebiotic Supplementation on Metabolic Parameters, Liver Aminotransferases, and Systemic Inflammation in Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J. Food Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yaghooti, H., Ghanavati, F., Seyedian, S.S., Cheraghian, B., and Mohammadtaghvaei, N. (2021). The Efficacy of Calcitriol Treatment in Non-Alcoholic Fatty Liver Patients with Different Genotypes of Vitamin D Receptor FokI Polymorphism. BMC Pharmacol. Toxicol., 22.","DOI":"10.1186\/s40360-021-00485-y"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.clnu.2020.11.037","article-title":"A Randomized Controlled Clinical Trial Comparing Calcitriol versus Cholecalciferol Supplementation to Reduce Insulin Resistance in Patients with Non-Alcoholic Fatty Liver Disease","volume":"40","author":"Mahmoudi","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/dom.14129","article-title":"Vitamin D for Treatment of Non-alcoholic Fatty Liver Disease Detected by Transient Elastography: A Randomized, Double-blind, Placebo-controlled Trial","volume":"22","author":"Zanko","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rahimpour, Z., Hoseini, R., and Behpour, N. (2022). Alterations of Liver Enzymes and Lipid Profile in Response to Exhaustive Eccentric Exercise: Vitamin D Supplementation Trial in Overweight Females with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02457-w"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104770","DOI":"10.1016\/j.phrs.2020.104770","article-title":"Oleoylethanolamide Supplementation in Obese Patients Newly Diagnosed with Non-Alcoholic Fatty Liver Disease: Effects on Metabolic Parameters, Anthropometric Indices, and Expression of PPAR-\u03b1, UCP1, and UCP2 Genes","volume":"156","author":"Tutunchi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12944-020-01283-x","article-title":"Chia (Salvia Hispanica)-Supplemented Diet Ameliorates Non-Alcoholic Fatty Liver Disease and Its Metabolic Abnormalities in Humans","volume":"19","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1017\/S0007114520001403","article-title":"Effect of Garlic Powder Supplementation on Hepatic Steatosis, Liver Enzymes and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomised Controlled Clinical Trial","volume":"124","author":"Sangouni","year":"2020","journal-title":"Br. J. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/ptr.7146","article-title":"Effects of Garlic Powder Supplementation on Metabolic Syndrome Components, Insulin Resistance, Fatty Liver Index, and Appetite in Subjects with Metabolic Syndrome: A Randomized Clinical Trial","volume":"35","author":"Sangouni","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2000419","DOI":"10.1002\/mnfr.202000419","article-title":"Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men\u2014A Randomized Controlled Trial","volume":"64","author":"Kruse","year":"2020","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4982080","DOI":"10.1155\/2022\/4982080","article-title":"Sesame Oil Ameliorates Alanine Aminotransferase, Aspartate Aminotransferase, and Fatty Liver Grade in Women with Nonalcoholic Fatty Liver Disease Undergoing Low-Calorie Diet: A Randomized Double-Blind Controlled Trial","volume":"2022","author":"Atefi","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Masnadi Shirazi, K., Shirinpour, E., Masnadi Shirazi, A., and Nikniaz, Z. (2021). Effect of Cranberry Supplementation on Liver Enzymes and Cardiometabolic Risk Factors in Patients with NAFLD: A Randomized Clinical Trial. BMC Complement. Med. Ther., 21.","DOI":"10.1186\/s12906-021-03436-6"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/09637486.2020.1746957","article-title":"Combined Cranberry Supplementation and Weight Loss Diet in Non-Alcoholic Fatty Liver Disease: A Double-Blind Placebo-Controlled Randomized Clinical Trial","volume":"71","author":"Hormoznejad","year":"2020","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1002\/ptr.7249","article-title":"The Effect of Pomegranate Extract on Anthropometric Indices, Serum Lipids, Glycemic Indicators, and Blood Pressure in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Double-blind Clinical Trial","volume":"35","author":"Goodarzi","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e14852","DOI":"10.1111\/ijcp.14852","article-title":"Does Naringenin Supplementation Improve Lipid Profile, Severity of Hepatic Steatosis and Probability of Liver Fibrosis in Overweight\/Obese Patients with NAFLD? A Randomised, Double-blind, Placebo-controlled, Clinical Trial","volume":"75","author":"Namkhah","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","article-title":"The Efficacy of Flaxseed and Hesperidin on Non-Alcoholic Fatty Liver Disease: An Open-Labeled Randomized Controlled Trial","volume":"75","author":"Yari","year":"2021","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102322","DOI":"10.1016\/j.ctim.2020.102322","article-title":"Effects of Curcuminoids on Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"49","author":"Keshvari","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"ref_62","first-page":"25","article-title":"The Effect of Curcumin Phytosome on the Treatment of Patients with Non-Alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"Volume 1308","author":"Barreto","year":"2021","journal-title":"Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of Phytosomal Curcumin on Anthropometric Parameters, Insulin Resistance, Cortisolemia and Non-Alcoholic Fatty Liver Disease Indices: A Double-Blind, Placebo-Controlled Clinical Trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jbmt.2020.02.021","article-title":"Effects of Non-Linear Resistance Training and Curcumin Supplementation on the Liver Biochemical Markers Levels and Structure in Older Women with Non-Alcoholic Fatty Liver Disease","volume":"24","author":"Kelardeh","year":"2020","journal-title":"J. Bodyw. Mov. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jcp.29870","article-title":"Expression of NF-\u03baB, IL-6, and IL-10 Genes, Body Composition, and Hepatic Fibrosis in Obese Patients with NAFLD\u2014Combined Effects of Oleoylethanolamide Supplementation and Calorie Restriction: A Triple-blind Randomized Controlled Clinical Trial","volume":"236","author":"Tutunchi","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2001178","DOI":"10.1002\/mnfr.202001178","article-title":"Effect of Mastiha Supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial","volume":"65","author":"Amerikanou","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"105753","DOI":"10.1016\/j.phrs.2021.105753","article-title":"Mastiha Has Efficacy in Immune-Mediated Inflammatory Diseases through a MicroRNA-155 Th17 Dependent Action","volume":"171","author":"Amerikanou","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"683028","DOI":"10.3389\/fimmu.2021.683028","article-title":"Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD","volume":"12","author":"Kanoni","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ptr.6826","article-title":"Effect of Sour Tea Supplementation on Liver Enzymes, Lipid Profile, Blood Pressure, and Antioxidant Status in Patients with Non-alcoholic Fatty Liver Disease: A Double-blind Randomized Controlled Clinical Trial","volume":"35","author":"Izadi","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102290","DOI":"10.1016\/j.ctim.2019.102290","article-title":"Effect of Green Coffee Extract Supplementation on Serum Adiponectin Concentration and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Controlled Trial","volume":"49","author":"Hosseinabadi","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102494","DOI":"10.1016\/j.ctim.2020.102494","article-title":"Delta-Tocotrienol Supplementation Improves Biochemical Markers of Hepatocellular Injury and Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled Trial","volume":"52","author":"Pervez","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1002\/ptr.7279","article-title":"The Effects of Co-administration of Artichoke Leaf Extract Supplementation with Metformin and Vitamin E in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"35","author":"Majnooni","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ptr.6937","article-title":"Protective Effects of Propolis on Hepatic Steatosis and Fibrosis among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Evaluated by Real-time Two-dimensional Shear Wave Elastography: A Randomized Clinical Trial","volume":"35","author":"Soleimani","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101259","DOI":"10.1016\/j.ctcp.2020.101259","article-title":"The Effects of Sumac (Rhus coriaria L.) Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"41","author":"Kazemi","year":"2020","journal-title":"Complement. Ther. Clin. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Jinato, T., Chayanupatkul, M., Dissayabutra, T., Chutaputti, A., Tangkijvanich, P., and Chuaypen, N. (2022). Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study. Nutrients, 14.","DOI":"10.3390\/nu14142921"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12967-022-03579-1","article-title":"A New Nutraceutical (Livogen Plus\u00ae) Improves Liver Steatosis in Adults with Non-Alcoholic Fatty Liver Disease","volume":"20","author":"Ferro","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fendo.2020.00494","article-title":"Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-Diabetic Individuals Aged Over 50 Years","volume":"11","author":"Ferro","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"126635","DOI":"10.1016\/j.jtemb.2020.126635","article-title":"The Effects of Zinc Supplementation on Metabolic Profile and Oxidative Stress in Overweight\/Obese Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"Fathi","year":"2020","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12011-019-02015-8","article-title":"The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight\/Obese Patients with Mild to Moderate Non-Alcoholic Fatty Liver Following Calorie-Restricted Diet: A Double-Blind, Randomized Placebo-Controlled Trial","volume":"197","author":"Fathi","year":"2020","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/ptr.6791","article-title":"The Effect of Saffron Supplementation on Some Inflammatory and Oxidative Markers, Leptin, Adiponectin, and Body Composition in Patients with Nonalcoholic Fatty Liver Disease: A Double-blind Randomized Clinical Trial","volume":"34","author":"Kavianipour","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"126659","DOI":"10.1016\/j.jtemb.2020.126659","article-title":"A Pilot Study of the Effects of Chromium Picolinate Supplementation on Serum Fetuin-A, Metabolic and Inflammatory Factors in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled Trial","volume":"63","author":"Moradi","year":"2021","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e150996","DOI":"10.1172\/JCI150996","article-title":"Dietary Sugar Restriction Reduces Hepatic de Novo Lipogenesis in Adolescent Boys with Fatty Liver Disease","volume":"131","author":"Cohen","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pedi.13011","article-title":"Associations of Physical Activity and Fitness with Hepatic Steatosis, Liver Enzymes, and Insulin Resistance in Children with Overweight\/Obesity","volume":"21","author":"Medrano","year":"2020","journal-title":"Pediatr. Diabetes"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Mascar\u00f3, C.M., Bouzas, C., Montemayor, S., Casares, M., Llompart, I., Ugarriza, L., Borr\u00e0s, P.-A., Mart\u00ednez, J.A., and Tur, J.A. (2022). Effect of a Six-Month Lifestyle Intervention on the Physical Activity and Fitness Status of Adults with NAFLD and Metabolic Syndrome. Nutrients, 14.","DOI":"10.3390\/nu14091813"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e20399","DOI":"10.1097\/MD.0000000000020399","article-title":"Simple Resistance Exercise Decreases Cytokeratin 18 and Fibroblast Growth Factor 21 Levels in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Clinical Study","volume":"99","author":"Takahashi","year":"2020","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1038\/s41598-022-10481-9","article-title":"Effects of Exercise on NAFLD Using Non-Targeted Metabolomics in Adipose Tissue, Plasma, Urine, and Stool","volume":"12","author":"Babu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ando.2020.05.003","article-title":"Impact of Aerobic Training with and without Whole-Body Vibration Training on Metabolic Features and Quality of Life in Non-Alcoholic Fatty Liver Disease Patients","volume":"81","author":"Saldiran","year":"2020","journal-title":"Ann. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e00316","DOI":"10.14309\/ctg.0000000000000316","article-title":"Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"12","author":"Charatcharoenwitthaya","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/acm.2019.0182","article-title":"Electroacupuncture Versus Aerobic Interval Training on Liver Functions in Patients with Nonalcoholic Fatty Liver","volume":"26","author":"Draz","year":"2020","journal-title":"J. Altern. Complement. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1620\/tjem.252.23","article-title":"Hybrid Training System Improves Insulin Resistance in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study","volume":"252","author":"Iwanaga","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e19471","DOI":"10.1097\/MD.0000000000019471","article-title":"Effects of High-Intensity Interval and Moderate-Intensity Continuous Aerobic Exercise on Diabetic Obese Patients with Nonalcoholic Fatty Liver Disease: A Comparative Randomized Controlled Trial","volume":"99","author":"Abdelbasset","year":"2020","journal-title":"Medicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1152\/ajpendo.00019.2020","article-title":"HDL-ApoA-I Kinetics in Response to 16 Wk of Exercise Training in Men with Nonalcoholic Fatty Liver Disease","volume":"318","author":"Whyte","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_93","first-page":"274","article-title":"The Interrelationship Among Non-Alcoholic Fatty Liver Disease, Colonic Diverticulosis and Metabolic Syndrome","volume":"30","author":"Milovanovic","year":"2021","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpdd.790","article-title":"Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function","volume":"10","author":"Yoon","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.dld.2020.09.021","article-title":"Antioxidant Activity of Hydroxytyrosol and Vitamin E Reduces Systemic Inflammation in Children with Paediatric NAFLD","volume":"53","author":"Mosca","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12664-020-01131-x","article-title":"Efficacy of Combining Pentoxiphylline and Vitamin E versus Vitamin E Alone in Non-Alcoholic Steatohepatitis\u2014 A Randomized Pilot Study","volume":"40","author":"Kedarisetty","year":"2021","journal-title":"Indian J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Civelek, M., and Podszun, M.C. (2022). Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. Antioxidants, 11.","DOI":"10.3390\/antiox11071284"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Panera, N., Braghini, M.R., Crudele, A., Smeriglio, A., Bianchi, M., Condorelli, A.G., Nobili, R., Conti, L.A., De Stefanis, C., and Lioci, G. (2022). Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis. Nutrients, 14.","DOI":"10.3390\/nu14183791"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e10459","DOI":"10.15252\/msb.202110459","article-title":"Combined Metabolic Activators Therapy Ameliorates Liver Fat in Nonalcoholic Fatty Liver Disease Patients","volume":"17","author":"Zeybel","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1515\/jpem-2020-0642","article-title":"Effect of L-Carnitine Supplementation on Children and Adolescents with Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","volume":"34","author":"Saneian","year":"2021","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clnesp.2021.08.005","article-title":"Effect of L-Carnitine Supplementation on Liver Fat Content and Cardiometabolic Indices in Overweight\/Obese Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial","volume":"46","author":"Sangouni","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the Effects of Three Kinds of Glucose-lowering Drugs on Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Randomized, Open-label, Three-arm, Active Control Study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the Effects of Tofogliflozin and Pioglitazone in Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus (ToPiND Study): A Randomized Prospective Open-Label Controlled Trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The Effects of Dapagliflozin on Hepatic and Visceral Fat in Type 2 Diabetes Patients with Non-alcoholic Fatty Liver Disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable Effect of Sodium\u2013Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Non-alcoholic Fatty Liver Disease Compared with Pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone Even at Low Dosage Improves NAFLD in Type 2 Diabetes: Clinical and Pathophysiological Insights from a Subgroup of the TOSCA.IT Randomised Trial","volume":"178","author":"Russo","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-020-00344-1","article-title":"Gender Differences in the Efficacy of Pioglitazone Treatment in Nonalcoholic Fatty Liver Disease Patients with Abnormal Glucose Metabolism","volume":"12","author":"Yan","year":"2021","journal-title":"Biol. Sex Differ."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of Tofogliflozin and Pioglitazone for NAFLD: Extension to the ToPiND Randomized Controlled Trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"866189","DOI":"10.3389\/fendo.2022.866189","article-title":"Effects of Sitagliptin on Intrahepatic Lipid Content in Patients with Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Seo, H.-Y., Lee, S.-H., Han, E., Hwang, J.S., Han, S., Kim, M.K., and Jang, B.K. (2022). Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911636"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of Exenatide and Insulin Glargine on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised Clinical Trial: Semaglutide versus Placebo Reduced Liver Steatosis but Not Liver Stiffness in Subjects with Non-alcoholic Fatty Liver Disease Assessed by Magnetic Resonance Imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of Dulaglutide on Liver Fat in Patients with Type 2 Diabetes and NAFLD: Randomised Controlled Trial (D-LIFT Trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/met.2022.0014","article-title":"Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease","volume":"20","author":"Xiao","year":"2022","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of Liraglutide Therapy on Serum Fetuin A in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or Insulin Glargine Treatments Improves Hepatic Fat in Obese Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease in Twenty-Six Weeks: A Randomized Placebo-Controlled Trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","article-title":"Combined exenatide and dapagliflozin Has No Additive Effects on Reduction of Hepatocellular Lipids despite Better Glycaemic Control in Patients with Type 2 Diabetes Mellitus Treated with Metformin: EXENDA, a 24-week, Prospective, Randomized, Placebo-controlled Pilot Trial","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and Dapagliflozin Combination Improves Markers of Liver Steatosis and Fibrosis in Patients with Type 2 Diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Cho, Y., Rhee, H., Kim, Y., Lee, M., Lee, B.-W., Kang, E.S., Cha, B.-S., Choi, J.-Y., and Lee, Y. (2022). Ezetimibe Combination Therapy with Statin for Non-Alcoholic Fatty Liver Disease: An Open-Label Randomized Controlled Trial (ESSENTIAL Study). BMC Med., 20.","DOI":"10.1186\/s12916-022-02288-2"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised Clinical Trial: Pemafibrate, a Novel Selective Peroxisome Proliferator-activated Receptor \u03b1 Modulator (SPPARM\u03b1), versus Placebo in Patients with Non-alcoholic Fatty Liver Disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic Acid as a Means of Preventing Atherosclerosis, Steatosis and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Xue, J., Liang, S., Ma, J., and Xiao, Y. (2022). Effect of Growth Hormone Therapy on Liver Enzyme and Other Cardiometabolic Risk Factors in Boys with Obesity and Nonalcoholic Fatty Liver Disease. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00967-y"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cen.14344","article-title":"Effect of Recombinant Human Growth Hormone on Liver Fat Content in Young Adults with Nonalcoholic Fatty Liver Disease","volume":"94","author":"Pan","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.ctim.2020.102452","article-title":"The Effect of Melatonin on Treatment of Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double Blind Clinical Trial","volume":"52","author":"Bahrami","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males with Metabolic Abnormalities","volume":"72","author":"Parks","year":"2020","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of Fatty Acid Synthase with FT-4101 Safely Reduces Hepatic de Novo Lipogenesis and Steatosis in Obese Subjects with Non-alcoholic Fatty Liver Disease: Results from Two Early-phase Randomized Trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"100474","DOI":"10.1016\/j.xcrm.2021.100474","article-title":"Pharmacodynamic Effects of Direct AMP Kinase Activation in Humans with Insulin Resistance and Non-Alcoholic Fatty Liver Disease: A Phase 1b Study","volume":"2","author":"Fouqueray","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic Inhibition of Ketohexokinase Prevents Fructose-Induced Metabolic Dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of Ketohexokinase in Adults with NAFLD Reduces Liver Fat and Inflammatory Markers: A Randomized Phase 2 Trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Shih, P.-H., Shiue, S.-J., Chen, C.-N., Cheng, S.-W., Lin, H.-Y., Wu, L.-W., and Wu, M.-S. (2021). Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin\/Adiponectin Axis. Mar. Drugs, 19.","DOI":"10.3390\/md19030148"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S2468-1253(20)30216-8","article-title":"Lubiprostone in Patients with Non-Alcoholic Fatty Liver Disease: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"5","author":"Kessoku","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jamcollsurg.2020.08.761","article-title":"Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial","volume":"231","author":"Yasukawa","year":"2020","journal-title":"J. Am. Coll. Surg."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised Clinical Trial: A Phase 2 Double-blind Study of Namodenoson in Non-alcoholic Fatty Liver Disease and Steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-Label Phase II Study Evaluating Safety and Efficacy of the Non-Steroidal Farnesoid X Receptor Agonist PX-104 in Non-Alcoholic Fatty Liver Disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e016334","DOI":"10.1161\/JAHA.119.016334","article-title":"Effects of Epeleuton, a Novel Synthetic Second-Generation N-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers","volume":"9","author":"Climax","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel Antisense Inhibition of Diacylglycerol O-Acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.31658","article-title":"Myeloid-Cell\u2013Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis","volume":"74","author":"Hou","year":"2021","journal-title":"Hepatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12944-022-01689-9","article-title":"Danshao Shugan Granule Therapy for Non-Alcoholic Fatty Liver Disease","volume":"21","author":"Wang","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Taha, M.M., Aneis, Y.M., Mohamady, H.M., Alrasheedy, S.A., and Elsayed, S.H. (2021). Effect of Focused Ultrasound Cavitation Augmented with Aerobic Exercise on Abdominal and Intrahepatic Fat in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0250337"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/gutjnl-2020-323608","article-title":"Safety and Efficacy of Hydrothermal Duodenal Mucosal Resurfacing in Patients with Type 2 Diabetes: The Randomised, Double-Blind, Sham-Controlled, Multicentre REVITA-2 Feasibility Trial","volume":"71","author":"Mingrone","year":"2022","journal-title":"Gut"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"102430","DOI":"10.1016\/j.nano.2021.102430","article-title":"Circulating Extracellular Vesicles Are a Biomarker for NAFLD Resolution and Response to Weight Loss Surgery","volume":"36","author":"Nakao","year":"2021","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e12393","DOI":"10.1111\/cob.12393","article-title":"Bariatric Surgery during the Evolution of Fatty Liver\u2013A Randomized Clinical Trial Comparing Gastric Bypass and Sleeve Gastrectomy Based on Transient Elastography","volume":"10","author":"Barros","year":"2020","journal-title":"Clin. Obes."},{"key":"ref_149","first-page":"129","article-title":"Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: A randomized controlled trial","volume":"40","author":"Dong","year":"2020","journal-title":"Zhongguo Zhen Jiu Chin. Acupunct. Moxibustion"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1852\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:42:58Z","timestamp":1760121778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,26]]},"references-count":149,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12051852"],"URL":"https:\/\/doi.org\/10.3390\/jcm12051852","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,26]]}}}